Covington Represents Oxford Immunotec in its $591M Acquisition by PerkinElmer
January 25, 2021
LONDON—Covington advised Nasdaq-listed Oxford Immunotec Global PLC in its agreement to be acquired by PerkinElmer, Inc., in a deal valued at approximately $591 million.
Under the terms of the acquisition, Oxford Immunotec shareholders will be entitled to receive $22.00 in cash for each outstanding ordinary share. The terms of the acquisition value Oxford Immunotec’s entire issued and to be issued ordinary share capital at approximately $591 million. The acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders.
Oxford Immunotec is a global, high-growth diagnostics company. Headquartered in Abingdon, UK, Oxford Immunotec is recognized for its proprietary test kits for latent tuberculosis.
PerkinElmer is a US-based corporation focused in the business areas of diagnostics, life science research, food, environmental, and industrial testing.
The cross-office team was led by James Gubbins and Jack Bodner, and included Gustavo Akkerman, Ben Land-Maycock, Katy Knight, Alicia Zhang, and Hannah Berry (M&A), Guy Dingley and Ansgar Simon (Tax), Jenny Park O'Shanick (Securities), Jenna Wallace and Antonio Michaelides (Employee Benefits), Morag Peberdy (IP), Scott Danzis (FDA Regulatory), Stefanie Doebler (Healthcare), Joshua Gray and Daniel Pavin (IT), Libbie Canter (Privacy), and Miranda Cole and Kristin Shaffer (Antitrust).
Back
